Author

Bruce Yacyshyn 1

1 University of Cincinnati,Cincinnati,United States

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF A SELECTIVE, ORAL SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD (APD334), IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE OASIS STUDY

William Sandborn, Laurent Peyrin-Biroulet, Luba Trokan, Jinkun Zhang, Tanja Kühbacher, Michael Chiorean, Scott D. Lee, Severine Vermeire, Bruce Yacyshyn, Snehal U. Naik, Preston Klassen, Julian Panés

CORRELATION BETWEEN CLINICAL AND ENDOSCOPIC ENDPOINTS AND REMISSION PER INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORE IN PATIENTS WITH CROHN'S DISEASE: DATA FROM CELEST

Remo Panaccione, Stefan Schreiber, Gert Van Assche, Walter Reinisch, Edouard Louis, Timothy Zisman, Bruce Yacyshyn, Subrata Ghosh, Shariar Sedghi, Sasikiran Goteti, Wan-Ju Lee, Ana P. Lacerda

Preclinical and Clinical Efficacy of Olorinab, a Peripherally Restricted, Highly Selective Full Agonist of the Cannabinoid Type 2 Receptor for the Management of Visceral Pain in Inflammatory Bowel Disease

Bruce Yacyshyn, Stuart M. Brierley, Beatriz Lindstrom, John Adams, Stewart Turner, Brett A. English, Kathe Stauber, Peter D.R. Higgins

Item 1 - 3 / 5
1